NAD+animalAnimal model2019

Insights into the inhibitory mechanisms of NADH on the αγ heterodimer of human NAD-dependent isocitrate dehydrogenase.

Scientific reports

confidence

Key findings

Structural study shows NADH inhibits human NAD-IDH by occupying NAD+ and ADP/citrate binding sites; biochemical data confirm competitive inhibition.

View source on PubMed (PMID 29453450) ↗

Sample size
N/A
Population
In vitro human NAD-dependent isocitrate dehydrogenase (NAD-IDH) enzymes
Dosing
NADH binding to enzyme
Duration
N/A
Route
in vitro
Blinding
not_reported
Controls
none
Drug class
coenzyme
Full abstract

Human NAD-dependent isocitrate dehydrogenase (NAD-IDH) catalyzes the oxidative decarboxylation of isocitrate in the citric acid cycle. In the α2βγ heterotetramer of NAD-IDH, the γ subunit plays the regulatory role and the β subunit the structural role. Previous biochemical data have shown that mammalian NAD-IDHs can be inhibited by NADH; however, the molecular mechanism is unclear. In this work, we show that the αβ, αγ and α2βγ enzymes of human NAD-IDH can be inhibited by NADH, and further determine the crystal structure of the αγ heterodimer bound with an Mg2+ and an NADH at the active site and an NADH at the allosteric site, which resembles that of the inactive αMgγ heterodimer. The NADH at the active site occupies the binding site for NAD+ and prevents the binding of the cofactor. The NADH at the allosteric site occupies the binding sites for ADP and citrate and blocks the binding of the activators. The biochemical data confirm that the NADH binding competes with the binding of NAD+ and the binding of citrate and ADP, and the two effects together contribute to the NADH inhibition on the activity. These findings provide insights into the inhibitory mechanisms of the αγ heterodimer by NADH.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.